Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-07-05
2005-07-05
Chen, Shin-Lin (Department: 1632)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S320100, C424S093200, C424S093210, C536S023500, C536S024100
Reexamination Certificate
active
06913926
ABSTRACT:
Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian breast or ovarian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene (PTTG)2 peptide, which has the ability to regulate endogenous PTTG1 expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG2-encoding polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG1. Other embodiments are directed to peptide-based treatments that deliver PTTG2 peptide molecules to the cells, which inhibit endogenous PTTG1 expression and/or PTTG1 function. Kits useful in practicing the inventive method are also disclosed.
REFERENCES:
patent: 5474897 (1995-12-01), Weiss et al.
patent: 5844107 (1998-12-01), Hanson et al.
patent: 5877302 (1999-03-01), Hanson et al.
patent: 5972900 (1999-10-01), Ferkol, Jr. et al.
patent: 5972901 (1999-10-01), Ferkol, Jr. et al.
patent: 6072041 (2000-06-01), Davis et al.
patent: 6077835 (2000-06-01), Hanson et al.
patent: 7322892 (1995-12-01), None
patent: 9173053 (1997-07-01), None
patent: WO 93/25712 (1993-12-01), None
patent: WO 95/25809 (1995-09-01), None
patent: WO 98/22587 (1998-05-01), None
patent: WO 90/09442 (1998-08-01), None
patent: WO 98/39412 (1998-09-01), None
Rudinger, 1976, Peptide Hormones, Edited by Parsons, University Park Press, Baltimore, p. 1-7.
Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al., 2000, Trends in Biotech, vol. 18, p. 34-39.
Eck et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 1996, McGraw-Hill, New York, p. 77-101.
Deonarain, M., 1998, Exp. Opin. Ther. Patents, vol. 8, No. 1, p. 53-69.
Verma et al., 1997, Nature, vol. 389, p. 239-242.
Gorecki, D., 2001, Expert Opin. Emerging Drugs, vol. 6, No. 2, p. 187-198.
PCT International Search Report—PCT/US 97/21463, Nov. 22, 1997.
Marra, M., et al., “The WashU-HHMI Mouse EST Project, AC W81747”, EMBL Database, Jun. 27, 1996, Heidelberg, XP002066845.
Hillier, L., et al., The WashU-Merck EST project, AC AA007646, EMBL Database, Jul. 28, 1996, Heidelberg, XP002066846.
Holton, T., et al., “ACQ57612”, EMBL Database, Sep. 5, 1994, Heidelberg, XP002066847.
Nippon Telegraph and Telephone Corp.: “ACQ75553”, EMBL Database, Aug. 4, 1995, Heidelberg, XP002066848.
Gonsky, R., et al., “Transforming DNA Sequences Present in Human Prolactin-Secreting Pituitary Tumors”, Molec. Endocrin., 5(11): 1687-1695, Nov. 1991.
Pei, L., et al., “Isolates and Characterization of a Pituitary Tumor-Transforming Gene (PTTG)”, Molec. Endocrin., 11(4):433-441, Apr. 1997.
Shimon, L., et al., “Genetic Basis of Endocrine Disease”, J. Clin. Endocrin. And Metab., 82(6): 1675-1681, Jun. 1997.
Chen, L., et al., “Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization.”, 1: Gene May 2, 2000, 248(102): 41-50. Abstract Only.
Heaney, A.P., “Expression of pituitary-tumor transforming gene in colorectal tumours”, 1: Lancet Feb. 26, 2000; 355(9205):716-9.
Heaney, A.P., “Early involvement of Estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis”, 1: Nat Med Nov. 1999; 5(11): 1317-21.
Suhardja, A.S., et al., “Molecular pathogenesis of pituitary adenomas a review.”, Acta Neurochir (Wien) 1999: 141(7): 729-36. Abstract only.
Ren, R., et al., “Identification of a ten-amine acid proline-rich SH3 binding site.”, Science Feb. 19, 1993; 259(5098): 1157-61. Abstract only.
Liu, X., et al., “The v-SRC SH3 domain binds phosphatidylinositol 3′-kinase.”, Mol Cell Biol Sep. 1993; 13(9): 5225-32. Abstract only.
Gout, L., et al., “The CTPase dynamin binds to and is activated by a subset of SH3 domains.” Cel Oct. 8, 1993; 75(1): 25-36.
Yu, H., et al., “Solution structure of the SH3 domain of Src and identification of its ligan-binding site.” Science Dec. 4, 1992; 258(5088): 1665-8. Abstract only.
Lee, L.A., et al., “Cloning and expression of human cDNA encoding human homologue of pituitary tumor transforming gene.”, Biochem Mol. Biol Int May 1999; 47(5): 891-7. Abstract only.
Zou, H., et al., “Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis.”, Science Jul 16, 1999; 285(5426): 418-22. Abstract only.
Zhang, X., et al., “Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.” J Clin Endocrinol Metab Feb. 1999; 84(2): 761-7.
Prezant, T.R., et al., “An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: evidence hPTTG family.”, J. Clin. Endocrinol Metab Mar. 1999; 84(3): 1149-52.
Fujimoto, N., et al., “Establishment of an estrogen responsive rat pituitary cell sub-line MtTe-2.” Endocr J Jun. 1999; 46(3): 389-96. Abstract only.
Ramos-Morales, F., et al., “Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product.”, Oncogene Jan. 20, 2000; 19(3): 403-9. Abstract only.
McCabe C.J., et al., “PTTG—a new pituitary tumour transforming gene.”, J. Endocrinol Aug. 1999; 162(2): 163-6. Abstract only.
Kakar, S.S., “Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG).”, Gene Nov. 29, 1999; 240(2): 317-24. Abstract only.
Dominguez, A., et al., “hpttg, a human homologue of a rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional function of hPTTG.”, Oncogene Oct. 29, 1998; 17(17): 2187-93. Abstract only.
Pet, L., “Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells.”, J Biol Chem Jan. 29, 1999; 274(5): 3151-8.
Saez, C., et al., “hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias.”, Oncogene Sep. 23, 1999; 18(39): 5473-6. Abstract only.
Pei, L., “Genomic Organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene.”, J Biol Chem Feb. 27, 1998; 273(9): 5219-25.
Wang, Z., et al., “Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter.”, Endocrinology Feb. 2000; 141(2): 763-71.
Zhang, X., et al., “Structure, expression, and function of human pituitary tumor-transforming gene (PTTG).”, Mol Endocrinol Jan. 1999; 13(1): 156-66.
Heaney, Anthony, P., et al., “Pituitary tumor transforming gene: a novel factor in pituitary tumour formation,” Balliere's Clinical Endocrinology and Metabolism, vol. 13, No. 3, pp. 367-380, 1999.
Freeman, G. J. et al.,Engagement of the PD-1 Immunoinhibitory receptor by a Novel B7 family Member Leads to Negative Regulation of Lymphocyte Activation, J. Exp Med,192(7):1027-1034 (Oct. 2, 2000). Abstract only.
George, J. et al.,Adoptive Transfer of beta(2)-Glycoprotein 1-Reactive Lymphocytes Enhances Early Atherosclerosis in LDL Receptor-Deficient Mice, Circulation,102(15):1822-1827 (Oct. 10, 2000). Abstract only.
Griffin, J. M. et al.,CD4(+)T-Cell Activation and Induction of Autoimmune Hepatitis following Trichloroetheylene Treatment in MRL+/+Mice, Toxicol Sci,57(2):345-352 (Oct. 2000). Abstract only.
Grom, A. A. et al.,T-cell and T-cell receptor abnormalities in the immunopathogenesis of juvenile theumatoid arthritis, Curr Opin Rheumatol,12(5):420-4 (Sep. 2000). Abstract only.
Han, W. R. et al.,Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mi
Heaney Anthony P.
Melmed Shlomo
Prezant Toni Rita
Cedars-Sinai Medical Center
Chen Shin-Lin
Pillsbury & Winthrop LLP
LandOfFree
Method of regulating biological activity of pituitary tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of regulating biological activity of pituitary tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of regulating biological activity of pituitary tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3430169